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Solute Carrier Family 11A Member 1 (SLC11A1) is a member of a highly conserved 
group of ion transporters and has restricted localisation to the phagosomal membrane of 
monocytes/macrophages. SLC11A1 plays an immunomodulatory role in influencing 
macrophage activation status and the T helper 1/T helper 2 bias. As such it modulates 
susceptibility to infectious/autoimmune diseases. A polymorphic (GT)n promoter 
microsatellite repeat is known to alter SLC11A1 promoter activity. Of the nine (GT)n 
alleles identified, alleles 3 and 2, which account for a combined allele frequency of 
greater than 95%, drive high and low SLC11A1 expression, respectively. The increased 
SLC11A1 expression, driven by (GT)n allele 3 is hypothesised to result in a heightened 
activation status of classically activated macrophages, affording resistance to infectious 
disease, but conferring susceptibility to pro-inflammatory autoimmune diseases. 
Conversely, decreased SLC11A1 expression in the presence of allele 2 would confer 
susceptibility to infectious disease, but resistance to autoimmune disease. 
 
A large number of studies assessing the association between the presence of specific 
(GT)n promoter alleles with the incidence of infectious and autoimmune disease have 
produced inconsistent associations. Meta-analyses are powerful analytical tools which 
combine individual association studies to estimate the strength of an association, 
therefore, meta-analyses of case control association studies (from 1991-2006) analysing 
the association of SLC11A1 promoter (GT)n alleles 2 and 3 with the incidence of 
autoimmune disease were performed. The meta-analyses found a weak predominance of 
disease in the absence of allele 2, with a fixed effects pooled OR of 0.80 (95% CI = 
0.22), however, a random effects pooled odds ratio (OR) of 0.88 (95% CI = 0.66) for 
allele 3 suggested no association with the incidence of autoimmune disease. 
 
The publication of additional case control studies between 2006 and the present allowed 
a more comprehensive meta-analysis to be completed. This analysis, which included 
additional SLC11A1 polymorphisms, represents the largest study assessing the 
association of SLC11A1 polymorphisms with disease occurrence to date. Allele 2 of the 
(GT)n microsatellite was associated with increased and reduced incidence of infectious 
[OR=1.32 (1.20-1.46)] and autoimmune diseases [OR=0.90 (0.81-1.00)], respectively. 
Allele 3 was significantly associated with reduced incidence of infectious disease 
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[OR=0.82 (0.76-0.88)], however, the association with susceptibility to autoimmune 
disease occurrence did not reach statistical significance [OR=1.11 (0.98-1.26)]. The 
findings of the meta-analysis challenges the hypothesis that allele 3 is the disease 
causing variant at the (GT)n microsatellite repeat. 
 
The results of these meta-analyses highlight small sample sizes as a major limitation of 
case control association studies. Completion of large-scale studies has been impractical 
because conventional SLC11A1 (GT)n genotyping methodologies are time consuming 
and cannot differentiate all (GT)n variants. A high resolution melt curve methodology 
has been designed and optimised to genotype two SLC11A1 polymorphisms, the (GT)n 
and (CAAA)n microsatellite repeats. Assay validation yielded a 100% success rate for 
genotyping of the (GT)n and (CAAA)n microsatellites. The designed methodology is the 
first to enable accurate, sensitive and high-throughput genotyping of these 
microsatellites and will enable the completion of sufficiently large association studies 
required to determine the association between the SLC11A1 (GT)n and (CAAA)n 
polymorphisms and disease occurrence. 
 
In addition to the (GT)n microsatellite, the -237C/T polymorphism has also been shown 
to modulate SLC11A1 expression, with the T variant driving low expression in the 
presence of (GT)n allele 3. Little is known about SLC11A1 transcription or the 
mechanism by which the (GT)n and -237C/T promoter polymorphisms modulate 
SLC11A1 expression. Bioinformatic studies were completed to identify putative 
regulatory elements involved in transcription and promoter constructs, containing 
different lengths of the SLC11A1 promoter, were prepared and used to assess promoter 
function. A 581bp promoter region (-532 to +49) that controlled SLC11A1 expression in 
monocytes was identified. Within this region was identified a 148bp minimal promoter 
region (-99 to +49) containing the core elements for the formation of the basal 
transcriptional complex. The greatest transcriptional enhancement was identified within 
a 170bp region (-532 to -362) containing a novel IRF-Ets composite sequence for the 
recruitment of transcription factors IRF-8 and PU.1. Additionally, the promoter 
constructs suggested that the SLC11A1 promoter may mediate bidirectional 
transcription. It was further determined that, in monocytic cells, the ability of (GT)n 
alleles 2 and 3 to differentially modulate SLC11A1 expression was not due to their 
differing abilities to form Z-DNA, but to monocyte-specific factor(s) binding to a 165bp 
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region (-362 to -197) of the SLC11A1 promoter. Additional bioinformatic and functional 
assays suggested that the T variant of the -237C/T polymorphism reduced SLC11A1 
promoter activity independently of the (GT)n microsatellite repeat. 
 
Infectious and autoimmune diseases are major contributors to morbidity and mortality. 
SLC11A1 is instrumental in regulating macrophage function and hence susceptibility to 
infectious and autoimmune diseases. This study has provided insight into the association 
of SLC11A1 with disease incidence, has developed a novel genotyping methodology to 
allow the completion of large association studies and has elucidated mechanisms of 
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LIST OF ABBREVIATIONS 
γ-IRE   interferon-γ response element 
ALL   acute lymphocytic leukaemia 
AML   acute myeloid leukaemia 
AMML  acute myelomonocytic leukaemia 
AP1   Activator protein 1 
ARNT   aryl hydrocarbon receptor nuclear translocator 
bp   base pairs 
BRE   TFIIB-recognition element 
BSA   bovine serum albumin 
CCF2-AM  coumarin cephalosporin fluorescein 
C/EBP  CCAAT/enhancer binding protein 
CI   confidence interval 
Ct   cycle threshold 
DCE   downstream core element 
DMEM  Dulbecco’s modified eagle medium 
DNA   deoxyribonucleic acid 
DPE   downstream promoter element 
EDTA   ethylenediaminetetraacetic acid 
EMSA   electrophoretic mobility shift assays 
FBS   fetal bovine serum 
GM-CSF  granulocyte macrophage colony-stimulating factor 
h   hours 
HBSS   Hanks buffered salt solution 
HIF-1   Hypoxia inducible factor 1 
HIV   Human immunodeficiency virus 
Idd   insulin dependant diabetes (murine) 
IDDM   insulin dependant diabetes mellitus (human) 
IECS   IRF-Ets composite sequence 
IFN-γ    interferon-gamma 
IL    interleukin 
iNOS   inducible nitric oxide synthase 
Inr   Initiator element 
IRF   interferon regulatory factors 
ISRE   IFN-stimulated response element 
kb   kilobase 
KLF   kruppel-like factor 
l   litre 
Lamp1  lysosome-associated membrane protein 1 
LB   Luria Bertani 
LD   linkage disequilibrium 
LPS    lipopolysaccharide 
MHC    major histocompatibility complex 
min   minutes 
MTE   motif ten element 
NF-IL6  nuclear factor IL-6 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NO   nitric oxide 
xxxiii 
 
Nramp  natural resistance-associated macrophage protein 
NTC   no template control 
Oct-1   octamer binding protein 1 
OR   odds ratio 
PAS   periodic acid-schiff 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PMA   phorbol myristate acetate 
PMN   polymorphonuclear 
pol II   RNA polymerase II 
PU.1   protein encoded by SPI-1 gene 
RES   reticuloendothelial system 
RNA   ribonucleic acid 
RNase   ribonuclease 
RPMI   Roswell Park Memorial Institute 
RT   room temperature 
s   seconds 
SBB   Sudan black B 
SLC11A1   Solute carrier family 11A member 1 (Human protein) 
SLC11A1  Solute carrier family 11A member 1 (Human gene) 
Slc11a1  Solute carrier family 11A member 1 (non-human protein) 
Slc11a1  Solute carrier family 11A member 1 (non-human gene) 
SLC11A2  Solute carrier family 11A member 2 (Human protein) 
SLC11A2  Solute carrier family 11A member 2 (Human gene) 
SNP   single nucleotide polymorphism 
Sp1   Specificity protein 1 
SPI-1   spleen focus by forming virus proviral integration 1 
TAF   TBP associated factor 
TBP   TATA binding protein 
TESS   Transcription Element Search Software 
TFIID   transcription factor II D 
TFBS   transcription factor binding site 
Th1    T helper 1 
Th2    T helper 2 
Tm   melting temperature 
TNF-α    tumour necrosis factor-alpha 
TSS1   transcription start site 1 
TSS2   transcription start site 2 
UV   ultraviolet 
XCPE1  X core promoter element 1 
YY1   Ying-Yang 1 
ZBP-1   Z-DNA binding protein 1 
 
